N-(1H-indol-7-yl)-4-methylbenzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1H-indol-7-yl)-4-methylbenzenesulfonamide
• 化学式: C₁₅H₁₄N₂O₂S
• 分子量: 286.354
• InChiKey: WVHPRRFRSLNGNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  70.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,5-己二酮 、 N-(1H-indol-7-yl)-4-methylbenzenesulfonamide 在 对甲苯磺酸 作用下， 以 乙醇 为溶剂， 反应 36.0h， 以99%的产率得到N-(5,8-dimethyl-9H-carbazol-1-yl)-4-methylbenzenesulfonamide
  参考文献：
  名称：

  Benzenesulfonamide derivatives and pharmaceutical composition thereof

  摘要：

  公开号：

  EP2366687B1
• 作为产物：
  描述：

  7-硝基吲哚-2-甲酸 在 copper(II) oxide 铁粉 、 氯化铵 作用下， 以 喹啉 、 水 、 异丙醇 为溶剂， 反应 8.5h， 生成 N-(1H-indol-7-yl)-4-methylbenzenesulfonamide
  参考文献：
  名称：

  Benzenesulfonamide derivatives and pharmaceutical composition thereof

  摘要：

  公开号：

  EP2366687B1

文献信息

• C7‐Indole Amidations and Alkenylations by Ruthenium(II) Catalysis
  作者：Isaac Choi、Antonis M. Messinis、Lutz Ackermann

  DOI：10.1002/anie.202006164

  日期：2020.7.20

  C7−H‐functionalized indoles are ubiquitous structural units of biological and pharmaceutical compounds for numerous antiviral agents against SARS‐CoV or HIV‐1. Thus, achieving site‐selective functionalizations of the C7−H position of indoles, while discriminating among other bonds, is in high demand. Herein, we disclose site‐selective C7−H activations of indoles by ruthenium(II) biscarboxylate catalysis

  C7-H-功能化吲哚是生物和药物化合物中普遍存在的结构单元，可用于多种针对 SARS-CoV 或 HIV-1 的抗病毒药物。因此，迫切需要实现吲哚 C7−H 位置的位点选择性功能化，同时区分其他键。在此，我们公开了在温和条件下通过二羧酸钌(II)催化对吲哚进行位点选择性C7-H活化。通过弱O配位的碱辅助内部亲电型取代C-H钌化使得吲哚的C7-H功能化，并提供了广泛的范围，包括C-N和C-C键的形成。多功能钌催化的 C7−H 活化的特点是克级合成和导向基团的无痕去除，从而可以轻松获得药物相关的支架。通过光谱和光谱分析进行的详细机理研究揭示了钌催化吲哚 C7−H 位置功能化的独特性质。
• NOVEL FUSED PYROLE DERIVATIVE
  申请人：Sone Toshihiko

  公开号：US20100190768A1

  公开（公告）日：2010-07-29

  The present invention relates to a compound represented by the formula (1) which is useful as a glucocorticoid receptor function regulating agent, an anti-inflammatory agent or an antidiabetic agent, or a pharmaceutically acceptable salt thereof: wherein R 1 is aralkyl, etc.; R 2 is H, etc.; —W 4 ═W 5 —W 6 ═W 7 — is a group of the formula: —CR 4 ═CR 5 —CR 6 ═CR 7 — (in which R 4 , R 5 , R 6 and R 7 are independently a group of the formula: -E-A (E is a single bond, etc., A is H or nitro, etc.)), etc.; R 8 is a group of the formula: —OR 11 (R 11 is H, etc.), etc.; R 9 is trifluoromethyl, etc.; R 10 is a group of the formula: —[C(R 13 )(R 14 )] n —R 15 (R 13 and R 14 are independently H, etc., n is an integer of 0 to 10, R 15 is a group of the formula: N(R 18 )R 19 (R 18 and R 19 form a nitrogen-containing heteromonocycle together with a nitrogen atom to which they are bonded), etc.).

  本发明涉及一种化合物，其化学式为(1)，它可作为糖皮质激素受体功能调节剂、抗炎剂或抗糖尿病剂，或其药学上可接受的盐使用：其中R1为芳基烷基等；R2为H等；-W4═W5-W6═W7-为以下式的基团：-CR4═CR5-CR6═CR7-(其中R4、R5、R6和R7独立地为以下式的基团：-E-A(E为单键等，A为H或硝基等))等；R8为以下式的基团：-OR11(R11为H等)等；R9为三氟甲基等；R10为以下式的基团：-[C(R13)(R14)]n-R15(R13和R14独立地为H等，n为0到10的整数，R15为以下式的基团：N(R18)R19(R18和R19与它们连接的氮原子一起形成含氮杂单环)等。
• NOVEL FUSED PYRROLE DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1930320A1

  公开（公告）日：2008-06-11

  The present invention relates to a compound represented by the formula (1) which is useful as a glucocorticoid receptor function regulating agent, an anti-inflammatory agent or an antidiabetic agent, or a pharmaceutically acceptable salt thereof: wherein R1 is aralkyl, etc.; R2 is H, etc.; -W4=W5-W6=W7- is a group of the formula: -CR4=CR5-CR6=CR7- (in which R4, R5, R6 and R7 are independently a group of the formula: -E-A (E is a single bond, etc., A is H or nitro, etc.)), etc.; R8 is a group of the formula: -OR11 (R11 is H, etc.), etc.; R9 is trifluoromethyl, etc.; R10 is a group of the formula: -[C(R13)(R14)]n-R15 (R13 and R14 are independently H, etc., n is an integer of 0 to 10, R15 is a group of the formula: N(R18)R19 (R18 and R19 form a nitrogen-containing heteromonocycle together with a nitrogen atom to which they are bonded), etc.).

  本发明涉及一种由式（1）表示的化合物，它可用作糖皮质激素受体功能调节剂、抗炎剂或抗糖尿病剂，或其药学上可接受的盐： 其中 R1 是芳烷基等；R2 是 H 等；-W4=W5-W6=W7- 是式中的基团：-CR4=CR5-CR6=CR7-（其中 R4、R5、R6 和 R7 独立地是式子中的一个基团：-E-A（E 是单键等，A 是 H 或硝基等））等； R8 是式中的基团：-OR11（R11 是 H 等）等； R9 是三氟甲基等； R10 是式中的基团：-[C(R13)(R14)]n-R15（R13 和 R14 独立地为 H 等，n 为 0 至 10 的整数，R15 为式中的基团：N(R18)R19（R18 和 R19 与它们键合的氮原子一起形成含氮杂单环）等）。
• Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle
  作者：Takashi Owa、Hiroshi Yoshino、Tatsuo Okauchi、Kentaro Yoshimatsu、Yoichi Ozawa、Naoko Hata Sugi、Takeshi Nagasu、Nozomu Koyanagi、Kyosuke Kitoh

  DOI：10.1021/jm9902638

  日期：1999.9.1

  Described herein is the discovery of a novel series of antitumor sulfonamides targeting G1 phase of the cell cycle. Cell cycle control in G1 phase has attracted considerable attention in recent cancer research, because many of the important proteins involved in G1 progression or G1/S transition have been found to play a crucial role in proliferation, differentiation, transformation, and programmed cell death (apoptosis). We previously reported our first antitumor sulfonamide E7010 as a novel tubulin polymerization inhibitor. Interestingly enough, continuous research on structurally related compounds led us to the finding of another class of antitumor sulfonamides that block cell cycle progression of P388 murine leukemia cells in GI phase, but not in M phase. Of the compounds examined, N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide (E7070) showed significant antitumor activity against HCT116 human colon carcinoma both in vitro (IC50 0.11 mu g/mL in cell proliferation assay) and in vivo (not only growth suppression but also a marked reduction of tumor size in nude mice). Because of its promising efficacy against human tumor xenografts and its unique mode of action, E7070 is currently undergoing phase I clinical trials in European countries.
• Benzenesulfonamide derivatives and pharmaceutical composition therof
  申请人：Chern Ji-Wang

  公开号：US20110230651A1

  公开（公告）日：2011-09-22

  The present invention is related to derivatives of benzenesulfonamide represented by formula (I), and the pharmaceutical composition thereof. In addition, the benzenesulfonamide derivatives disclosed in the present invention can serve as potential cell cycle inhibitors, and thereby these benzenesulfonamide derivatives and the pharmaceutical composition thereof can be antitumor drug candidates, which might aim at cell cycle. Particularly, the benzenesulfonamide derivatives disclosed in the present invention may function as antitumor drugs to treat solid cancers.